Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma

Serge van Ruth(The Netherlands Cancer Institute), F.A.N. Zoetmulder(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Victor J. Verwaal(The Netherlands Cancer Institute), Catharina M. Korse(The Netherlands Cancer Institute)
Anti-Cancer Drugs
January 1, 2003
10.1097/00001813-200301000-00008
Cited by 31

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884